All In Biotech

Free tool

FAERS Monitor: Oxytrol For Women

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 202211 or its brand name (Oxytrol For Women, Oxybutynin). Reports on generic versions are filed under their own applications.

Reports

28,263

Serious

13,571

48% of reports

Hospitalization

6,767

Death reported

1,688

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective3,815
  • fatigue1,549
  • fall1,463
  • off label use1,258
  • nausea1,218
  • dizziness1,122
  • diarrhoea1,110
  • pain1,071
  • urinary tract infection1,045
  • headache986
  • pruritus950
  • asthenia900
  • application site erythema826
  • rash792
  • dyspnoea745

Reports by year received

View as table
YearReports
2004178
2005196
2006150
200743
200855
200990
2010345
2011572
2012725
20131,492
20145,252
20152,300
20161,799
20171,880
20182,030
20192,054
20201,776
20211,500
20221,477
20231,350
20241,023
20251,144
2026831

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,025,896 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
application site erythemaSignal82624.222.617,779
urinary tract infectionSignal1,0454.64.32,928
fallSignal1,4633.33.12,345
drug ineffectiveSignal3,8152.22.12,519
pruritus9501.81.7370
asthenia9001.81.7314
dizziness1,1221.71.6312
fatigue1,5491.51.4251
rash7921.41.374
pain1,0711.31.275
diarrhoea1,1101.31.270
headache9861.21.125
nausea1,2181.11.123
off label use1,2581.11.06
dyspnoea7451.00.90

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.